# Naurex, Inc, an affiliate of Allergan plc trials: 20 (2026)

ClinicalTrials.gov lists 20 trials with Naurex, Inc, an affiliate of Allergan plc as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Naurex, Inc, an affiliate of Allergan plc: 20 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/naurex-inc-an-affiliate-of-allergan-plc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 27, 2019 | NCT03855865 | Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Withdrawn | Depressive Disorder, Major | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03855865) |
| January 24, 2019 | NCT03814733 | Assessment of Effect of Rapastinel on Driving Performance | Naurex, Inc, an affiliate of Allergan plc | Phase 1 | Completed | Driving Performance | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03814733) |
| January 10, 2019 | NCT03799900 | Assessment of Abuse Potential of Rapastinel in Humans | Naurex, Inc, an affiliate of Allergan plc | Phase 1 | Completed | Human Abuse Potential | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03799900) |
| September 18, 2018 | NCT03675776 | Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD) | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Terminated | Depressive Disorder, Major | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03675776) |
| September 12, 2018 | NCT03668600 | Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Terminated | Depressive Disorder, Major | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03668600) |
| August 3, 2018 | NCT03614156 | Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Terminated | Depressive Disorder, Major | 363 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03614156) |
| June 18, 2018 | NCT03560518 | Study of Rapastinel as Monotherapy in Patients With MDD | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Terminated | Depressive Disorder, Major | 439 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03560518) |
| November 24, 2017 | NCT03352453 | A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder | Naurex, Inc, an affiliate of Allergan plc | Phase 2 | Terminated | Depressive Disorder, Major | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03352453) |
| December 23, 2016 | NCT03002077 | Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Completed | Depressive Disorder, Major | 617 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03002077) |
| November 1, 2016 | NCT02951988 | A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Completed | Depressive Disorder, Major | 1,304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02951988) |
| October 24, 2016 | NCT02943577 | A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Completed | Depressive Disorder, Major | 429 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02943577) |
| October 24, 2016 | NCT02943564 | A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Completed | Depressive Disorder, Major | 658 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02943564) |
| October 13, 2016 | NCT02932943 | A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) | Naurex, Inc, an affiliate of Allergan plc | Phase 3 | Completed | Depressive Disorder, Major | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02932943) |
| February 19, 2015 | NCT02366364 | Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers | Naurex, Inc, an affiliate of Allergan plc | Phase 1 | Completed | Major Depressive Disorder | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02366364) |
| July 16, 2014 | NCT02192099 | Open Label Extension for GLYX13-C-202, NCT01684163 | Naurex, Inc, an affiliate of Allergan plc | Phase 2 | Terminated | Major Depressive Disorder | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02192099) |
| February 20, 2014 | NCT02067793 | Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder | Naurex, Inc, an affiliate of Allergan plc | Phase 2 | Completed | Major Depressive Disorder | 151 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02067793) |
| May 17, 2013 | NCT01856556 | Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers | Naurex, Inc, an affiliate of Allergan plc | Phase 1 | Completed | Healthy | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01856556) |
| September 12, 2012 | NCT01684163 | Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants | Naurex, Inc, an affiliate of Allergan plc | Phase 2 | Completed | Major Depressive Disorder | 369 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01684163) |
| November 4, 2010 | NCT01234558 | Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression | Naurex, Inc, an affiliate of Allergan plc | Phase 2 | Completed | Major Depressive Disorder | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01234558) |
| November 17, 2009 | NCT01014650 | Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers | Naurex, Inc, an affiliate of Allergan plc | Phase 1 | Completed | Healthy | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01014650) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 5 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Terminated | 6 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Depressive Disorder, Major | 16 |
| Depression | 6 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Psychology practices in the United States](https://specstream.ai/data/businesses/psychology-practices/united-states)
- [Damage restoration companies in the United States](https://specstream.ai/data/businesses/damage-restoration-companies/united-states)
- [Pubs in the United States](https://specstream.ai/data/businesses/pubs/united-states)
- [Dental laboratories in the United States](https://specstream.ai/data/businesses/dental-laboratories/united-states)
- [Real estate firms in the United States](https://specstream.ai/data/businesses/real-estate-firms/united-states)
- [Diners in the United States](https://specstream.ai/data/businesses/diners/united-states)
